Marker Therapeutics, Inc.
5.10%
659,901
1094038
57055L107
Aug 14, 2025
Aug 19, 2025, 02:42 PM
Reporting Persons (1)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | Individual | 5.10% | 659,901 | 659,901 | 0 |
Disclosure Items (7)
Common Stock, Par Value $0.001
Marker Therapeutics, Inc.
2450 HOLCOMBE BLVD, HOUSTON, TX, 77021
This Schedule is being filed by John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 (the "Trust").
The Reporting Person's business address is 2100 Old Highway 8 NW, St. Paul, MN 55112.
The Reporting Person is a trust.
The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
The Reporting Person is the trustee of the revocable trust which holds the Common Stock.
The trustee of the Reporting Person received 6,060,783 shares of Common Stock and warrants to acquire 2,197, 944 shares of Common Stock of the Issuer acquired pursuant to a merger with Marker Cell Therapy, Inc. ("Marker Cell"). The Reporting Person was appointed to the Board of Directors of the Issuer. The Reporting Person was granted 12,500 options to acquire Common Stock of the Issuer upon joining the Board consistent with the Issuer's Non-Employee Director Compensation program. On January 26, 2023, the Issuer effected a one-for-ten (1-for-10) reverse stock split of its common stock and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. John R. Wilson transferred such shares to the Trust on November 30, 2021.
On the date hereof, the Reporting Person beneficially owns 659,901 shares of Common Stock, which comprises 5.10% of the Common Stock of the Issuer. As of, August 4, 2025, there were 12,938,910 shares of Common Stock of the Issuer issued and outstanding as represented by the Issuer's Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2025.
The Reporting Person has the sole power to vote the shares beneficially owned.
The transactions effected during the past 60 days by the Reporting Person are set forth on Exhibit A, attached hereto.
Only the Reporting Person has the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock reported by this statement.
Not applicable.
John R. Wilson resigned from the Issuer's Board of Directors on January 24, 2025.
1. Schedule A dated as of August 15, 2025.